Treating DNA Repair-deficient Breast Cancers

Several clinical trials are underway in which PARP inhibitors are being tested in breast cancers, mostly triple-negative breast cancers, because they often harbor BRCA mutations and DNA repair deficiencies. Emerging studies show that the benefit of PARP inhibitors could extend beyond breast cancers with germline BRCA mutations.

Read More

NextGen Grant Recipient Harnesses the Power of Genomics to Understand Pediatric Brain Cancer

Paul Northcott, PhD, inaugural recipient of the AACR NextGen Grant for Transformative Cancer Research, has dedicated his research career to understanding a type of brain cancer called medulloblastoma, with the ultimate goal of improving treatment and prognosis for patients.

Read More

AACR, NCI, and EORTC to Host Meeting on Molecular Targets

Beginning this Friday, Philadelphia will host the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference, held each year by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, brings together some of the world’s leading cancer scientists to discuss the discovery, biology, and clinical applications of novel cancer therapeutics.

Read More

Recent Advances in Measuring Response to Immune Checkpoint Inhibitors

In recent years, the U.S. Food and Drug Administration has approved immune checkpoint inhibitors, a class of immunotherapy, to treat 10 different types of cancer, in addition to solid tumors located anywhere in the body that have certain DNA damage and repair-related biomarkers. However, only a small percentage of patients respond to these treatments, and they can have significant side effects. Researchers are looking for biomarkers that can identify patients who are likely to respond to immune checkpoint inhibitors.

Read More

A Young Researcher Advocates for Strong Federal Funding

Scientific advancements are made through scientific research. From understanding the basic biology behind a disease to testing how well a drug targets a disease, the majority of this research is funded by the National Institutes of Health (NIH). So, on September 14, 2017, hundreds of people from 37 states and Washington, D.C., from over 300 institutes and organizations, gathered for the 5th Annual Rally for Medical Research with a common message

Read More